Abstract
Manipulation of alternative splicing is a unique way of regulating gene expression. Here, a detailed protocol is presented for modification of HER2 pre-mRNA alternative splicing. A 20-mer splice switching oligonucleotide (SSO) targeting exon 15 in HER2 pre-mRNA induced skipping of exon 15, resulted in significant downregulation of full-length HER2 mRNA and protein expression in HER2-overexpressing breast cancer cell line SK-BR-3.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Keren H, Lev-Maor G, Ast G (2010) Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 11:345–355
Blencowe B (2006) Alternative splicing: new insights from global analyses. Cell 126:37–47
Kim E, Goren A, Ast G (2007) Insights into the connection between cancer and alternative splicing. Trends Genet 24:7–10
Wood M, Yin H, McClorey G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3:e109
Sazani P, Graziewicz M, Kole R (2008) Splice switching oligonucleotides as potential therapeutics. In: Crooke S (ed) Antisense drug technology, 2nd edn. CRC Press LLC, Boca Raton, pp 89–114
van Ommen G, van Deutekom J, Aartsma-Rus A (2008) The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 10:140–149
Aartsma-Rus A, van Ommen G (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609–1624
Mercatante D, Mohler J, Kole R (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 277:49374–49382
Mercatante D, Bortner C, Cidlowski J, Kole R (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. J Biol Chem 276:16411–16417
Bruno I, Jin W, Cote G (2004) Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 13:2409–2420
Shiraishi T, Eysturskarð J, Nielsen P (2010) Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions. BMC Cancer 10:342
Shieh J-J, Liu K-T, Huang S-W, Chen Y-J, Hsieh T-Y (2009) Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dematol 129:2497–2506
Renshaw J, Orr R, Walton M, Te-Poele R, Williams R, Wancewicz E, Monia B, Workman P, Pritchard-Jones K (2004) Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol Cancer Ther 3:1467–1483
Pankratova S, Nielsen B, Shiraishi T, Nielsen P (2010) PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. Int J Oncol 36:29–38
Brambilla C, Folini M, Gandellini P, Daprai L, Daidone M, Zaffaroni N (2004) Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell Mol Life Sci 61:1764–1774
Wan J, Sazani P, Kole R (2009) Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer 124:772–777
Hynes N, Stern D (1994) The biology of erbB-2/neu-HER-2 and its role in cancer. Biochim Biophys Acta 1198:165–184
Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61:1–13
Moasser M (2006) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:6577–6592
Sierakowska H, Sambade M, Agrawal S, Kole R (1996) Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 93:12840–12844
Altschul S, Gish W, Miller W, Myers E, Lipman D (1990) Basic local alignment search tool. J Mol Biol 215:403–410
Cartegni L, Wang J, Zhu Z, Zhang M, Krainer A (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568–3571
Levin A, Yu R, Geary R (2008) Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke S (ed) Antisense drug technology. CRC Press LLC, Boca Raton, pp 183–215
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wan, J. (2012). Antisense-Mediated Exon Skipping to Shift Alternative Splicing to Treat Cancer. In: Aartsma-Rus, A. (eds) Exon Skipping. Methods in Molecular Biology, vol 867. Humana Press. https://doi.org/10.1007/978-1-61779-767-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-767-5_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-766-8
Online ISBN: 978-1-61779-767-5
eBook Packages: Springer Protocols